Skip to main content

Table 3 Most common adverse events stratified by BCCNS or non-BCCNS status

From: Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials

Selected AEs, n (%)

Erivance BCC

(N = 104)

EAS

(N = 119)

BCCNS

(n = 22)

Non-BCCNS

(n = 82)

BCCNS

(n = 19)

Non-BCCNS

(n = 100)

Any AE

22 (100)

82 (100)

18 (95)

98 (98)

Grade 3–5 AE

9 (41)

35 (43)

3 (16)

32 (32)

Alopecia

19 (86)

47 (57)

11 (58)

58 (58)

Muscle spasms

17 (77)

54 (66)

12 (63)

72 (72)

Weight decreased

15 (68)

33 (40)

1 (5)

18 (18)

Dysgeusia

13 (59)

40 (49)

14 (74)

70 (70)

Nausea

9 (41)

21 (26)

3 (16)

20 (20)

Fatigue

8 (36)

29 (35)

7 (37)

16 (16)

Diarrhea

7 (32)

16 (20)

3 (16)

27 (27)

Arthralgia

5 (23)

11 (13)

2 (11)

2 (2)

  1. AE adverse event, BCCNS basal cell carcinoma nevus syndrome, EAS expanded access study